ANDI
MCID: DBT091
MIFTS: 67

Diabetes Insipidus, Nephrogenic, Autosomal (ANDI)

Categories: Endocrine diseases, Genetic diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Diabetes Insipidus, Nephrogenic, Autosomal

MalaCards integrated aliases for Diabetes Insipidus, Nephrogenic, Autosomal:

Name: Diabetes Insipidus, Nephrogenic, Autosomal 58 76 41
Nephrogenic Diabetes Insipidus 12 77 25 54 26 60 30 6 15 74
Diabetes Insipidus, Nephrogenic 58 26 13 45
Congenital Nephrogenic Diabetes Insipidus 26 38 74
Vasopressin-Resistant Diabetes Insipidus 12 54 26
Nephrogenic Diabetes Insipidus, Autosomal 30 6
Nephrogenic Diabetes Insipidus, X-Linked 30 6
Adh-Resistant Diabetes Insipidus 26 74
Diabetes Insipidus Nephrogenic 54 56
Diabetes Insipidus, Nephrogenic, Type Ii 58
Diabetes Insipidus Nephrogenic X-Linked 54
Diabetes Insipidus, Nephrogenic Type 2 77
Diabetes Insipidus Nephrogenic Type 1 54
Diabetes Insipidus Nephrogenic Type 2 76
Adh Resistant Diabetes Insipidus 54
Diabetes Insipidus Renalis 26
Andi 76
Ndi 26

Characteristics:

Orphanet epidemiological data:

60
nephrogenic diabetes insipidus
Inheritance: Autosomal dominant,Autosomal recessive,X-linked recessive; Prevalence: 1-9/1000000 (Europe),1-9/1000000; Age of onset: Infancy,Neonatal;

OMIM:

58
Inheritance:
autosomal recessive
autosomal dominant

Miscellaneous:
genetic heterogeneity (see )
onset in first weeks of life
both autosomal dominant and autosomal recessive inheritance have been reported


HPO:

33
diabetes insipidus, nephrogenic, autosomal:
Inheritance heterogeneous autosomal dominant inheritance autosomal recessive inheritance
Onset and clinical course neonatal onset


Classifications:

Orphanet: 60  
Rare renal diseases


Summaries for Diabetes Insipidus, Nephrogenic, Autosomal

NIH Rare Diseases : 54 Nephrogenic diabetes insipidus is a disorder in which a defect in the small tubes (tubules) in the kidneys causes a person to produce a large amount of urine. Nephrogenic diabetes insipidus occurs when the kidney tubules, which allow water to be removed from the body or reabsorbed, do not respond to a chemical in the body called antidiuretic hormone (ADH) or vasopressin. ADH normally tells the kidneys to make the urine more concentrated. As a result of the defect, the kidneys release an excessive amount of water into the urine, producing a large quantity of very dilute urine. The most common symptoms are frequent urination (polyuria), especially during nighttime (nocturia), and drinking too much liquids (polydipsia). It can be either acquired or hereditary. The acquired form is brought on by certain drugs and chronic diseases and can occur at any time during life. About 90% of all cases of hereditary nephrogenic diabetes insipidus result from mutations in the AVPR2 gene, and about  10% of cases are caused by mutations in the AQP2 gene. Treatment consists of plenty of water intake; medication, such as thiazide diuretics and NSAIDs; and a low-salt, low-protein diet.

MalaCards based summary : Diabetes Insipidus, Nephrogenic, Autosomal, also known as nephrogenic diabetes insipidus, is related to diabetes insipidus, nephrogenic, x-linked and diabetes insipidus, neurohypophyseal. An important gene associated with Diabetes Insipidus, Nephrogenic, Autosomal is AQP2 (Aquaporin 2), and among its related pathways/superpathways are Vasopressin-regulated water reabsorption and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs Tolvaptan and Furosemide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are nephrogenic diabetes insipidus and hyposthenuria

Disease Ontology : 12 An impaired renal function disease characterized by a complete or partial resistance of the kidneys to vasopressin (ADH).

Genetics Home Reference : 26 Nephrogenic diabetes insipidus is a disorder of water balance. The body normally balances fluid intake with the excretion of fluid in urine. However, people with nephrogenic diabetes insipidus produce too much urine (polyuria), which causes them to be excessively thirsty (polydipsia). Affected individuals can quickly become dehydrated if they do not drink enough water, especially in hot weather or when they are sick.

OMIM : 58 Nephrogenic diabetes insipidus is caused by the inability of the renal collecting ducts to absorb water in response to antidiuretic hormone (ADH), also known as arginine vasopressin (AVP; 192340). Approximately 90% of patients are males with the X-linked recessive form, type I (304800), which is caused by mutation in the gene encoding the vasopressin V2 receptor (AVPR2; 300538). The remaining 10% of patients have the autosomal form, type II, caused by mutation in the AQP2 gene (Morello and Bichet, 2001). Neurogenic, or central, diabetes insipidus (CDI; 125700) is caused by mutation in the gene encoding arginine vasopressin, located on 20p13. (125800)

UniProtKB/Swiss-Prot : 76 Diabetes insipidus, nephrogenic, autosomal: A disorder caused by the inability of the renal collecting ducts to absorb water in response to arginine vasopressin. Characterized by excessive water drinking (polydipsia), excessive urine excretion (polyuria), persistent hypotonic urine, and hypokalemia. Inheritance can be autosomal dominant or recessive.

Wikipedia : 77 Nephrogenic diabetes insipidus (also known as renal diabetes insipidus) is a form of diabetes insipidus... more...

GeneReviews: NBK1177

Related Diseases for Diabetes Insipidus, Nephrogenic, Autosomal

Diseases related to Diabetes Insipidus, Nephrogenic, Autosomal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 diabetes insipidus, nephrogenic, x-linked 33.3 AQP2 AVPR2
2 diabetes insipidus, neurohypophyseal 31.6 AQP2 AVP AVPR2 LNPEP
3 nephrogenic syndrome of inappropriate antidiuresis 30.5 AVP AVPR2
4 bartter disease 30.2 CASR CLCNKA SLC12A1
5 polyhydramnios 30.1 AQP1 AQP3 SLC12A1
6 central pontine myelinolysis 30.1 AQP1 AQP4 AVP
7 diabetes insipidus 30.0 AQP2 ARHGAP4 AVP AVPR2 CLCNKA SLC12A1
8 meniere disease 29.1 AQP1 AQP2 AQP3 AQP4 AQP7 MIP
9 diabetes insipidus, nephrogenic, with mental retardation and intracerebral calcification 12.5
10 renal tubular acidosis 10.6
11 hydronephrosis 10.6
12 diabetes mellitus 10.5
13 fanconi syndrome 10.5
14 hyperparathyroidism 10.4
15 rickets 10.4
16 nephrocalcinosis 10.4
17 urinary tract obstruction 10.3
18 hereditary hypophosphatemic rickets 10.3
19 peripheral vertigo 10.3 AQP2 AVP
20 amyloidosis 10.3
21 renal tubular acidosis, distal 10.3
22 motion sickness 10.3 AQP1 AVP
23 idiopathic edema 10.3 AQP1 AQP2
24 hyperuricemia 10.3
25 vestibular disease 10.3 AQP2 AVP
26 familial hypocalciuric hypercalcemia 10.2 ARHGAP4 CASR
27 syndrome of inappropriate antidiuretic hormone 10.2 AQP2 AVP AVPR2
28 gestational diabetes insipidus 10.2 AVP LNPEP
29 graves disease 1 10.2
30 bartter syndrome, type 1, antenatal 10.2
31 hydrocephalus 10.2
32 cystinosis 10.2
33 primary hyperparathyroidism 10.2
34 bladder neck obstruction 10.2
35 ureteral obstruction 10.2
36 acquired immunodeficiency syndrome 10.2
37 hypervitaminosis d 10.2
38 subependymoma 10.1 AQP1 AQP4
39 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 10.1 AQP2 AQP3 AVP
40 arthrogryposis, renal dysfunction, and cholestasis 1 10.1
41 radiculopathy 10.1
42 hydrops, lactic acidosis, and sideroblastic anemia 10.1 AQP4 MIP
43 bullous keratopathy 10.1 AQP3 MIP
44 anorexia nervosa 10.1
45 ichthyosis prematurity syndrome 10.1
46 avoidant personality disorder 10.1
47 personality disorder 10.1
48 constipation 10.1
49 depression 10.1
50 spinal cord disease 10.0 AQP4 AVPR2

Comorbidity relations with Diabetes Insipidus, Nephrogenic, Autosomal via Phenotypic Disease Network (PDN):


Acute Cystitis Bipolar Disorder
Diabetes Insipidus

Graphical network of the top 20 diseases related to Diabetes Insipidus, Nephrogenic, Autosomal:



Diseases related to Diabetes Insipidus, Nephrogenic, Autosomal

Symptoms & Phenotypes for Diabetes Insipidus, Nephrogenic, Autosomal

Human phenotypes related to Diabetes Insipidus, Nephrogenic, Autosomal:

60 33 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nephrogenic diabetes insipidus 60 33 obligate (100%) Obligate (100%) HP:0009806
2 hyposthenuria 60 33 hallmark (90%) Very frequent (99-80%) HP:0003158
3 hypernatremia 60 33 hallmark (90%) Very frequent (99-80%) HP:0003228
4 hypernatremic dehydration 60 33 hallmark (90%) Very frequent (99-80%) HP:0004906
5 failure to thrive 60 33 frequent (33%) Frequent (79-30%) HP:0001508
6 nausea and vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002017
7 constipation 60 33 frequent (33%) Frequent (79-30%) HP:0002019
8 fever 60 33 frequent (33%) Frequent (79-30%) HP:0001945
9 polydipsia 60 33 frequent (33%) Frequent (79-30%) HP:0001959
10 anorexia 60 33 frequent (33%) Frequent (79-30%) HP:0002039
11 seizures 60 33 occasional (7.5%) Occasional (29-5%) HP:0001250
12 short stature 60 33 occasional (7.5%) Occasional (29-5%) HP:0004322
13 renal insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0000083
14 feeding difficulties 60 33 occasional (7.5%) Occasional (29-5%) HP:0011968
15 hydroureter 60 33 occasional (7.5%) Occasional (29-5%) HP:0000072
16 hypovolemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0011106
17 global developmental delay 60 33 very rare (1%) Very rare (<4-1%) HP:0001263
18 polyhydramnios 60 33 very rare (1%) Very rare (<4-1%) HP:0001561
19 enuresis nocturna 60 33 very rare (1%) Very rare (<4-1%) HP:0010677
20 intellectual disability 33 HP:0001249
21 feeding difficulties in infancy 33 HP:0008872
22 vomiting 33 HP:0002013
23 irritability 33 HP:0000737
24 growth delay 60 Occasional (29-5%)
25 megacystis 33 HP:0000021
26 unexplained fevers 33 HP:0001955
27 functional abnormality of the bladder 60 Occasional (29-5%)
28 polyuria 33 HP:0000103
29 hypertonic dehydration 33 HP:0001986

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
seizures
mental retardation can occur in patients with repeated episodes of dehydration

Abdomen Gastrointestinal:
constipation
polydipsia
vomiting
poor feeding

Neurologic Behavioral Psychiatric Manifestations:
irritability

Laboratory Abnormalities:
hypernatremia
high serum osmolality
inappropriately low urine osmolality
normal or increased levels of serum arginine vasopressin (antidiuretic hormone, )
normal extrarenal responses to ddavp administration
more
Genitourinary Bladder:
lower urinary tract dilatation may occur over time

Growth Other:
failure to thrive

Growth Height:
short stature

Metabolic Features:
unexplained fevers
hypertonic dehydration

Genitourinary Kidneys:
polyuria

Clinical features from OMIM:

125800

MGI Mouse Phenotypes related to Diabetes Insipidus, Nephrogenic, Autosomal:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 AQP1 AQP2 AQP3 AQP4 AVP AVPR2
2 growth/size/body region MP:0005378 10.06 AQP1 AQP2 AQP3 AQP4 AQP7 AVPR2
3 homeostasis/metabolism MP:0005376 10 AQP1 AQP2 AQP3 AQP4 AQP7 AVP
4 mortality/aging MP:0010768 9.85 AQP1 AQP2 AQP3 AQP4 AVP AVPR2
5 renal/urinary system MP:0005367 9.65 AQP1 AQP2 AQP3 AQP4 AQP7 AVP
6 vision/eye MP:0005391 9.1 AQP1 AQP3 AQP4 CASR L1CAM MIP

Drugs & Therapeutics for Diabetes Insipidus, Nephrogenic, Autosomal

Drugs for Diabetes Insipidus, Nephrogenic, Autosomal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolvaptan Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 150683-30-0 216237
2
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-31-9 3440
3
Conivaptan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 210101-16-9 151171
4
Metolazone Approved Phase 4,Phase 1 17560-51-9 4170
5
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
6 Natriuretic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Vasopressins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 arginine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Arginine Vasopressin Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Antidiuretic Hormone Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 diuretics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Sodium Potassium Chloride Symporter Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Coagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Pharmaceutical Solutions Phase 4,Phase 2
19 Torsemide Phase 4
20 Natriuretic Peptide, Brain Phase 4
21 Antihypertensive Agents Phase 4,Phase 1,Not Applicable
22 Sodium Chloride Symporter Inhibitors Phase 4,Phase 1,Not Applicable
23
Midodrine Approved Phase 2, Phase 3 133163-28-7, 42794-76-3 4195
24
Spironolactone Approved Phase 2, Phase 3,Not Applicable 1952-01-7, 52-01-7 5833
25
Metformin Approved Phase 3,Phase 1 657-24-9 14219 4091
26
Satavaptan Investigational Phase 3,Phase 2 185913-78-4 7029
27 Neurotransmitter Agents Phase 2, Phase 3,Not Applicable
28 Adrenergic Agonists Phase 2, Phase 3
29 Diuretics, Potassium Sparing Phase 2, Phase 3,Not Applicable
30 Adrenergic Agents Phase 2, Phase 3
31 Hormone Antagonists Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
32 Mineralocorticoids Phase 2, Phase 3,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
34 Peripheral Nervous System Agents Phase 2, Phase 3,Not Applicable
35 Sympathomimetics Phase 2, Phase 3
36 Autonomic Agents Phase 2, Phase 3
37 Adrenergic alpha-Agonists Phase 2, Phase 3
38 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3,Not Applicable
39 Hypoglycemic Agents Phase 3,Phase 1
40
Lithium carbonate Approved Phase 2 554-13-2
41
Atorvastatin Approved Phase 2 134523-00-5 60823
42
Mannitol Approved, Investigational Phase 2,Not Applicable 69-65-8 6251 453
43
carbamide peroxide Approved Phase 2 124-43-6
44
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
45
Nitric Oxide Approved Phase 2 10102-43-9 145068
46
Phentermine Approved, Illicit Phase 2 122-09-8 4771
47 SRX246 Phase 2,Phase 1
48 Antimetabolites Phase 2
49 Anticholesteremic Agents Phase 2
50 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
2 Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites Unknown status NCT01552590 Phase 4 Tolvaptan;Placebo
3 Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease Not yet recruiting NCT03949894 Phase 4 Tolvaptan
4 Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease Recruiting NCT03596957 Phase 4 Tolvaptan
5 Regional Tolvaptan Registry Recruiting NCT02666651 Phase 4 Tolvaptan
6 Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure Terminated NCT02352285 Phase 4 Tolvaptan;Placebo
7 Effects of Tolvaptan in Healthy Adults Completed NCT01973140 Phase 4 Tolvaptan;Hypertonic saline infusion
8 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
9 The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study Withdrawn NCT01663662 Phase 4 Tolvaptan;placebo
10 Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients Completed NCT01439009 Phase 4 Tolvaptan;Placebo of tolvaptan
11 Tolvaptan for Ascites in Cirrhotic Patients Completed NCT01292304 Phase 4 Tolvaptan
12 Tolvaptan in Hyponatremic Cancer Patients Completed NCT01199198 Phase 4 Tolvaptan;Placebo
13 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
14 Tolvaptan for Advanced or Refractory Heart Failure Recruiting NCT02959411 Phase 4 Tolvaptan;Standard of care diuretic therapy
15 A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia Completed NCT00435591 Phase 4 Conivaptan;placebo
16 Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure Completed NCT01863511 Phase 4 loop diuretic;tolvaptan
17 Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion Withdrawn NCT00806910 Phase 4 Conivaptan
18 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
19 Pilot Study of Using Copeptin to Predict Response to Tolvaptan Completed NCT01346072 Phase 4 tolvaptan
20 Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders Recruiting NCT02476409 Phase 4 tolvaptan
21 Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure Completed NCT02606253 Phase 4 tolvaptan;Chlorothiazide;Metolazone
22 Aquaresis Utility for Hyponatremic Acute Heart Failure Study Completed NCT02183792 Phase 4 Tolvaptan;Furosemide
23 Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients Completed NCT01752543 Phase 4 Conivaptan;Placebo (Dextrose)
24 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia Unknown status NCT01507727 Phase 2, Phase 3 Tolvaptan;Placebo
25 Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE) Unknown status NCT01733134 Phase 3 Tolvaptan;placebo
26 DILIPO (DILutIonal HyPOnatremia) Completed NCT00274326 Phase 3 SR121463B
27 Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites Completed NCT02173288 Phase 2, Phase 3 Standard medical therapy;Tolvaptan;Midodrine
28 Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD Completed NCT03803124 Phase 3 Tolvaptan;Placebo
29 Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure Recruiting NCT03772041 Phase 3 OPC-61815;Tolvaptan Tab 15 MG
30 Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload Recruiting NCT03255226 Phase 3 Tolvaptan
31 A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH Recruiting NCT03048747 Phase 3 Tolvaptan Oral Tablet
32 Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) Active, not recruiting NCT02964273 Phase 3 Tolvaptan;Matching Placebo
33 International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia Completed NCT02449044 Phase 3 Tolvaptan
34 A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia Withdrawn NCT02442674 Phase 3 Tolvaptan
35 Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Completed NCT02251275 Phase 3 Tolvaptan (OPC-41061)
36 Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease Completed NCT02160145 Phase 3 Tolvaptan (OPC-41061);Placebo
37 An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Terminated NCT02020278 Phase 3 Tolvaptan
38 Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia Terminated NCT02012959 Phase 3 Tolvaptan
39 Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema Completed NCT01651156 Phase 3 Tolvaptan;Placebo
40 Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure Completed NCT01618448 Phase 3 Tolvaptan;Placebo
41 Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management Completed NCT01584557 Phase 3 Tolvaptan or Samsca;placebo or sugar pill
42 Effect of Tolvaptan on Cognitive Function in Cirrhosis Completed NCT01556646 Phase 3 Tolvaptan
43 A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia Terminated NCT01451411 Phase 3 Conivaptan hydrochloride;Placebo
44 Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Completed NCT01349348 Phase 3 Tolvaptan;Tolvaptan;placebo
45 A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] Completed NCT01280721 Phase 3 tolvaptan
46 Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia Terminated NCT01227512 Phase 3 tolvaptan
47 Open-Label Tolvaptan Study in Subjects With ADPKD Completed NCT01214421 Phase 3 Tolvaptan
48 A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema Completed NCT01114828 Phase 3 OPC-41061;OPC-41061
49 A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema Completed NCT01050530 Phase 3 OPC-41061;Placebo
50 A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg Completed NCT01048788 Phase 3 OPC-41061

Search NIH Clinical Center for Diabetes Insipidus, Nephrogenic, Autosomal

Cochrane evidence based reviews: diabetes insipidus, nephrogenic

Genetic Tests for Diabetes Insipidus, Nephrogenic, Autosomal

Genetic tests related to Diabetes Insipidus, Nephrogenic, Autosomal:

# Genetic test Affiliating Genes
1 Nephrogenic Diabetes Insipidus, Autosomal 30 AQP2
2 Nephrogenic Diabetes Insipidus, X-Linked 30 AVPR2
3 Nephrogenic Diabetes Insipidus 30

Anatomical Context for Diabetes Insipidus, Nephrogenic, Autosomal

MalaCards organs/tissues related to Diabetes Insipidus, Nephrogenic, Autosomal:

42
Kidney, Heart, Liver, Brain, Prostate, Lung, Bone

Publications for Diabetes Insipidus, Nephrogenic, Autosomal

Articles related to Diabetes Insipidus, Nephrogenic, Autosomal:

(show top 50) (show all 688)
# Title Authors Year
1
Severe congenital nephrogenic diabetes insipidus in a compound heterozygote with a new large deletion of the AQP2 gene. A case report. ( 30784238 )
2019
2
Nephrogenic diabetes insipidus associated with prolonged sedation with sevoflurane in the intensive care unit. ( 30916031 )
2019
3
Nephrogenic diabetes insipidus after esophagectomy in a patient with remote history of lithium treatment: A case report. ( 30921589 )
2019
4
Long-term outcome in inherited nephrogenic diabetes insipidus. ( 30976394 )
2019
5
Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: a retrospective cohort study. ( 31007893 )
2019
6
A novel AVPR2 missense mutation in an Asian family with inherited nephrogenic diabetes insipidus: A case report. ( 31027113 )
2019
7
Renal Tubular Acidosis Presenting as Nephrogenic Diabetes Insipidus. ( 31064905 )
2019
8
Partial nephrogenic diabetes insipidus associated with Castleman's disease. ( 31088379 )
2019
9
Complete Nephrogenic Diabetes Insipidus After Prolonged Sevoflurane Sedation: A Case Report of 3 Cases. ( 30130280 )
2019
10
Genetic deletion of ADP-activated P2Y12 receptor ameliorates lithium-induced nephrogenic diabetes insipidus in mice. ( 30257062 )
2019
11
Nephrogenic Diabetes Insipidus. ( 30454745 )
2019
12
Nephrogenic diabetes insipidus in initial stage of acute lymphoblastic leukemia and relapse after haploidentical hematopoietic stem-cell transplantation: A case report. ( 29901649 )
2018
13
A Novel Mutation in the AVPR2 Gene Causing Congenital Nephrogenic Diabetes Insipidus ( 29991464 )
2018
14
Phenotype heterogeneity of congenital adrenal hyperplasia due to genetic mosaicism and concomitant nephrogenic diabetes insipidus in a sibling. ( 29996815 )
2018
15
Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial. ( 30012135 )
2018
16
Tamoxifen Decreases Lithium-Induced Natriuresis in Rats With Nephrogenic Diabetes Insipidus. ( 30050465 )
2018
17
Four Japanese Patients with Congenital Nephrogenic Diabetes Insipidus due to the AVPR2 Mutations. ( 30073107 )
2018
18
Double Trouble - Severe Hypernatremia Secondary to Central Diabetes Insipidus Complicated by Hypercalcemic Nephrogenic Diabetes Insipidus: A Case Report. ( 30120219 )
2018
19
Progranulin Deficient Mice Develop Nephrogenic Diabetes Insipidus. ( 30271659 )
2018
20
Systemic lupus erythematosus with Sjögren's syndrome and renal tubular acidosis presenting as nephrogenic diabetes insipidus. ( 29657217 )
2018
21
AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus. ( 29650969 )
2018
22
Novel and recurrent variants in AVPR2 in 19 families with X-linked congenital nephrogenic diabetes insipidus. ( 29594432 )
2018
23
Bartter Syndrome Type 1 Presenting as Nephrogenic Diabetes Insipidus. ( 29527380 )
2018
24
Treatment of congenital nephrogenic diabetes insipidus in pregnancy. ( 29512817 )
2018
25
Nephrogenic Diabetes Insipidus in Childhood: Assessment of Volume Status and Appropriate Fluid Replenishment. ( 29489607 )
2018
26
Use of acetazolamide in lithium-induced nephrogenic diabetes insipidus: a case report. ( 29479446 )
2018
27
Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus. ( 29478202 )
2018
28
Contiguous 22.1-kb deletion embracing AVPR2 and ARHGAP4 genes at novel breakpoints leads to nephrogenic diabetes insipidus in a Chinese pedigree. ( 29394883 )
2018
29
Tamoxifen attenuates development of lithium-induced nephrogenic diabetes insipidus in rats. ( 29357422 )
2018
30
Treatment regimens by pediatric nephrologists in children with congenital nephrogenic diabetes insipidus: A MWPNC study
. ( 29162216 )
2018
31
Functional characterization of AVPR2 mutants found in Turkish patients with nephrogenic diabetes insipidus. ( 29117938 )
2018
32
Value of Renal Biopsy in Diagnosing Infantile Nephropathic Cystinosis Associated With Secondary Nephrogenic Diabetes Insipidus. ( 28276300 )
2017
33
Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus. ( 28228402 )
2017
34
Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice. ( 28233082 )
2017
35
Hyperactivation of Nrf2 in early tubular development induces nephrogenic diabetes insipidus. ( 28233855 )
2017
36
Bartter Syndrome with Nephrogenic Diabetes Insipidus and Vitamin D Resistant Rickets. ( 28285303 )
2017
37
Role of adenylyl cyclase 6 in the development of lithium-induced nephrogenic diabetes insipidus. ( 28405619 )
2017
38
Congenital nephrogenic diabetes insipidus complicated with Hinman syndrome. ( 28504419 )
2017
39
Congenital nephrogenic diabetes insipidus in the Corpus Hippocraticum: The first description. ( 28742510 )
2017
40
Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus. ( 28139295 )
2017
41
Nephrogenic diabetes insipidus. ( 28134709 )
2017
42
A novel SLC12A1 gene mutation associated with hyperparathyroidism, hypercalcemia, nephrogenic diabetes insipidus, and nephrocalcinosis in four patients. ( 28095294 )
2017
43
Bendamustine-induced nephrogenic diabetes insipidus
. ( 27719738 )
2017
44
Novel de novo AVPR2 Variant in a Patient with Congenital Nephrogenic Diabetes Insipidus. ( 29177155 )
2017
45
Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update. ( 29125546 )
2017
46
Bendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis. ( 27780577 )
2017
47
Novel AVPR2 mutation causing partial nephrogenic diabetes insipidus in a Japanese family. ( 26974133 )
2016
48
A novel mutation affecting the arginine-137 residue of AVPR2 in dizygous twins leads to nephrogenic diabetes insipidus and attenuated urine exosome aquaporin-2. ( 27117808 )
2016
49
Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant). ( 27156763 )
2016
50
Pemetrexed-Induced Nephrogenic Diabetes Insipidus. ( 27241854 )
2016

Variations for Diabetes Insipidus, Nephrogenic, Autosomal

UniProtKB/Swiss-Prot genetic disease variations for Diabetes Insipidus, Nephrogenic, Autosomal:

76 (show all 28)
# Symbol AA change Variation ID SNP ID
1 AQP2 p.Gly64Arg VAR_004401 rs104894326
2 AQP2 p.Arg187Cys VAR_004402 rs104894328
3 AQP2 p.Ser216Pro VAR_004403 rs104894329
4 AQP2 p.Leu22Val VAR_015239 rs104894336
5 AQP2 p.Leu28Pro VAR_015240
6 AQP2 p.Ala47Val VAR_015241 rs995684800
7 AQP2 p.Asn68Ser VAR_015242 rs104894331
8 AQP2 p.Val71Met VAR_015243 rs149659001
9 AQP2 p.Thr125Met VAR_015244 rs104894333
10 AQP2 p.Thr126Met VAR_015245 rs104894330
11 AQP2 p.Ala147Thr VAR_015246 rs104894334
12 AQP2 p.Val168Met VAR_015247 rs755694590
13 AQP2 p.Gly175Arg VAR_015248 rs104894335
14 AQP2 p.Cys181Trp VAR_015249 rs104894337
15 AQP2 p.Pro185Ala VAR_015250 rs761713751
16 AQP2 p.Ala190Thr VAR_015251 rs104894341
17 AQP2 p.Trp202Cys VAR_015253
18 AQP2 p.Glu258Lys VAR_015254 rs104894332
19 AQP2 p.Pro262Leu VAR_015255 rs104894339
20 AQP2 p.Gln57Pro VAR_015256 rs28931580
21 AQP2 p.Gly100Val VAR_015257 rs104894338
22 AQP2 p.Ala70Asp VAR_062585
23 AQP2 p.Gly100Arg VAR_062586 rs130307620
24 AQP2 p.Gly180Ser VAR_062587 rs147039983
25 AQP2 p.Arg187His VAR_062588 rs193922495
26 AQP2 p.Arg254Leu VAR_062589
27 AQP2 p.Arg254Gln VAR_062590
28 AQP2 p.Thr108Met VAR_071370 rs146882829

ClinVar genetic disease variations for Diabetes Insipidus, Nephrogenic, Autosomal:

6 (show top 50) (show all 231)
# Gene Variation Type Significance SNP ID Assembly Location
1 AVPR2 AVPR2, 1-BP DEL, 733G deletion Pathogenic
2 AVPR2 NM_000054.4(AVPR2): c.395C> A (p.Ala132Asp) single nucleotide variant Pathogenic rs104894747 GRCh37 Chromosome X, 153171355: 153171355
3 AVPR2 NM_000054.4(AVPR2): c.395C> A (p.Ala132Asp) single nucleotide variant Pathogenic rs104894747 GRCh38 Chromosome X, 153905901: 153905901
4 AVPR2 NM_000054.4(AVPR2): c.553G> T (p.Gly185Cys) single nucleotide variant Pathogenic rs104894748 GRCh37 Chromosome X, 153171513: 153171513
5 AVPR2 NM_000054.4(AVPR2): c.553G> T (p.Gly185Cys) single nucleotide variant Pathogenic rs104894748 GRCh38 Chromosome X, 153906059: 153906059
6 AVPR2 NM_000054.4(AVPR2): c.614A> G (p.Tyr205Cys) single nucleotide variant Pathogenic rs104894749 GRCh37 Chromosome X, 153171574: 153171574
7 AVPR2 NM_000054.4(AVPR2): c.614A> G (p.Tyr205Cys) single nucleotide variant Pathogenic rs104894749 GRCh38 Chromosome X, 153906120: 153906120
8 AVPR2 NM_000054.4(AVPR2): c.607C> T (p.Arg203Cys) single nucleotide variant Pathogenic rs104894750 GRCh37 Chromosome X, 153171567: 153171567
9 AVPR2 NM_000054.4(AVPR2): c.607C> T (p.Arg203Cys) single nucleotide variant Pathogenic rs104894750 GRCh38 Chromosome X, 153906113: 153906113
10 AVPR2 NM_000054.4(AVPR2): c.337C> T (p.Arg113Trp) single nucleotide variant Pathogenic rs28935496 GRCh37 Chromosome X, 153171297: 153171297
11 AVPR2 NM_000054.4(AVPR2): c.337C> T (p.Arg113Trp) single nucleotide variant Pathogenic rs28935496 GRCh38 Chromosome X, 153905843: 153905843
12 AVPR2 AVPR2, 1-BP INS insertion Pathogenic
13 AVPR2 NM_000054.4(AVPR2): c.213G> A (p.Trp71Ter) single nucleotide variant Pathogenic rs104894751 GRCh37 Chromosome X, 153171173: 153171173
14 AVPR2 NM_000054.4(AVPR2): c.213G> A (p.Trp71Ter) single nucleotide variant Pathogenic rs104894751 GRCh38 Chromosome X, 153905719: 153905719
15 AVPR2 NM_000054.4(AVPR2): c.839A> G (p.Tyr280Cys) single nucleotide variant Pathogenic rs104894752 GRCh37 Chromosome X, 153171799: 153171799
16 AVPR2 NM_000054.4(AVPR2): c.839A> G (p.Tyr280Cys) single nucleotide variant Pathogenic rs104894752 GRCh38 Chromosome X, 153906345: 153906345
17 AVPR2 NM_000054.4(AVPR2): c.1009C> T (p.Arg337Ter) single nucleotide variant Pathogenic rs104894753 GRCh37 Chromosome X, 153172075: 153172075
18 AVPR2 NM_000054.4(AVPR2): c.1009C> T (p.Arg337Ter) single nucleotide variant Pathogenic rs104894753 GRCh38 Chromosome X, 153906621: 153906621
19 AVPR2 NM_000054.4(AVPR2): c.253G> A (p.Asp85Asn) single nucleotide variant Pathogenic rs104894754 GRCh37 Chromosome X, 153171213: 153171213
20 AVPR2 NM_000054.4(AVPR2): c.253G> A (p.Asp85Asn) single nucleotide variant Pathogenic rs104894754 GRCh38 Chromosome X, 153905759: 153905759
21 AVPR2 NM_000054.4(AVPR2): c.602G> A (p.Gly201Asp) single nucleotide variant Pathogenic rs104894755 GRCh37 Chromosome X, 153171562: 153171562
22 AVPR2 NM_000054.4(AVPR2): c.602G> A (p.Gly201Asp) single nucleotide variant Pathogenic rs104894755 GRCh38 Chromosome X, 153906108: 153906108
23 AVPR2 AVPR2, 1-BP INS, 804G insertion Pathogenic
24 AVPR2 NM_000054.5(AVPR2): c.102del (p.Leu35Cysfs) deletion Pathogenic GRCh38 Chromosome X, 153905608: 153905608
25 AVPR2 NM_000054.5(AVPR2): c.102del (p.Leu35Cysfs) deletion Pathogenic GRCh37 Chromosome X, 153171062: 153171062
26 AVPR2 NM_000054.4(AVPR2): c.410G> A (p.Arg137His) single nucleotide variant Pathogenic rs104894756 GRCh37 Chromosome X, 153171370: 153171370
27 AVPR2 NM_000054.4(AVPR2): c.410G> A (p.Arg137His) single nucleotide variant Pathogenic rs104894756 GRCh38 Chromosome X, 153905916: 153905916
28 AVPR2 NM_000054.4(AVPR2): c.541C> T (p.Arg181Cys) single nucleotide variant Pathogenic rs104894757 GRCh37 Chromosome X, 153171501: 153171501
29 AVPR2 NM_000054.4(AVPR2): c.541C> T (p.Arg181Cys) single nucleotide variant Pathogenic rs104894757 GRCh38 Chromosome X, 153906047: 153906047
30 AVPR2 NM_000054.4(AVPR2): c.313T> G (p.Phe105Val) single nucleotide variant Pathogenic rs104894758 GRCh37 Chromosome X, 153171273: 153171273
31 AVPR2 NM_000054.4(AVPR2): c.313T> G (p.Phe105Val) single nucleotide variant Pathogenic rs104894758 GRCh38 Chromosome X, 153905819: 153905819
32 AVPR2 NM_000054.4(AVPR2): c.137T> A (p.Ile46Lys) single nucleotide variant Pathogenic rs104894759 GRCh37 Chromosome X, 153171097: 153171097
33 AVPR2 NM_000054.4(AVPR2): c.137T> A (p.Ile46Lys) single nucleotide variant Pathogenic rs104894759 GRCh38 Chromosome X, 153905643: 153905643
34 AVPR2 NM_000054.4(AVPR2): c.310C> T (p.Arg104Cys) single nucleotide variant Pathogenic rs104894760 GRCh37 Chromosome X, 153171270: 153171270
35 AVPR2 NM_000054.4(AVPR2): c.310C> T (p.Arg104Cys) single nucleotide variant Pathogenic rs104894760 GRCh38 Chromosome X, 153905816: 153905816
36 AQP2 NM_000486.5(AQP2): c.559C> T (p.Arg187Cys) single nucleotide variant Pathogenic rs104894328 GRCh37 Chromosome 12, 50348446: 50348446
37 AQP2 NM_000486.5(AQP2): c.559C> T (p.Arg187Cys) single nucleotide variant Pathogenic rs104894328 GRCh38 Chromosome 12, 49954663: 49954663
38 AQP2 NM_000486.5(AQP2): c.439G> A (p.Ala147Thr) single nucleotide variant Pathogenic rs104894334 GRCh37 Chromosome 12, 50348016: 50348016
39 AQP2 NM_000486.5(AQP2): c.439G> A (p.Ala147Thr) single nucleotide variant Pathogenic rs104894334 GRCh38 Chromosome 12, 49954233: 49954233
40 AQP2 NM_000486.5(AQP2): c.223T> G (p.Cys75Gly) single nucleotide variant Likely pathogenic rs193922494 GRCh37 Chromosome 12, 50344836: 50344836
41 AQP2 NM_000486.5(AQP2): c.223T> G (p.Cys75Gly) single nucleotide variant Likely pathogenic rs193922494 GRCh38 Chromosome 12, 49951053: 49951053
42 AQP2 NM_000486.5(AQP2): c.438C> T (p.Phe146=) single nucleotide variant Likely benign rs143886391 GRCh37 Chromosome 12, 50348015: 50348015
43 AQP2 NM_000486.5(AQP2): c.438C> T (p.Phe146=) single nucleotide variant Likely benign rs143886391 GRCh38 Chromosome 12, 49954232: 49954232
44 AQP2 NM_000486.5(AQP2): c.560G> A (p.Arg187His) single nucleotide variant Likely pathogenic rs193922495 GRCh37 Chromosome 12, 50348447: 50348447
45 AQP2 NM_000486.5(AQP2): c.560G> A (p.Arg187His) single nucleotide variant Likely pathogenic rs193922495 GRCh38 Chromosome 12, 49954664: 49954664
46 AQP2 NM_000486.5(AQP2): c.785delC (p.Pro262Argfs) deletion Likely pathogenic rs193922496 GRCh37 Chromosome 12, 50349360: 50349360
47 AQP2 NM_000486.5(AQP2): c.785delC (p.Pro262Argfs) deletion Likely pathogenic rs193922496 GRCh38 Chromosome 12, 49955577: 49955577
48 AVPR2 NM_000054.4(AVPR2): c.176T> C (p.Leu59Pro) single nucleotide variant Likely pathogenic rs193922112 GRCh37 Chromosome X, 153171136: 153171136
49 AVPR2 NM_000054.4(AVPR2): c.176T> C (p.Leu59Pro) single nucleotide variant Likely pathogenic rs193922112 GRCh38 Chromosome X, 153905682: 153905682
50 AVPR2 NM_000054.4(AVPR2): c.290T> C (p.Leu97Pro) single nucleotide variant Likely pathogenic rs193922113 GRCh37 Chromosome X, 153171250: 153171250

Expression for Diabetes Insipidus, Nephrogenic, Autosomal

Search GEO for disease gene expression data for Diabetes Insipidus, Nephrogenic, Autosomal.

Pathways for Diabetes Insipidus, Nephrogenic, Autosomal

Pathways related to Diabetes Insipidus, Nephrogenic, Autosomal according to KEGG:

38
# Name Kegg Source Accession
1 Vasopressin-regulated water reabsorption hsa04962

Pathways related to Diabetes Insipidus, Nephrogenic, Autosomal according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.98 AQP1 AQP2 AQP3 AQP4 AQP7 AVP
2
Show member pathways
11.64 AQP1 AQP2 AQP3 AQP4 AQP7 AVP
3 11 AQP2 AQP3 AQP4 AVP AVPR2
4 10.72 CLCNKA SLC12A1

GO Terms for Diabetes Insipidus, Nephrogenic, Autosomal

Cellular components related to Diabetes Insipidus, Nephrogenic, Autosomal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.97 AQP1 AQP2 AQP3 AQP4 AQP7 AVPR2
2 integral component of plasma membrane GO:0005887 9.87 AQP1 AQP7 AVPR2 CASR CLCNKA LNPEP
3 apical plasma membrane GO:0016324 9.65 AQP1 AQP2 CASR MIP SLC12A1
4 plasma membrane GO:0005886 9.44 AQP1 AQP2 AQP3 AQP4 AQP7 AVPR2
5 basolateral plasma membrane GO:0016323 9.35 AQP1 AQP2 AQP3 AQP4 CASR
6 membrane GO:0016020 10.18 AQP1 AQP2 AQP3 AQP4 AQP7 AVPR2

Biological processes related to Diabetes Insipidus, Nephrogenic, Autosomal according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.92 AQP1 AQP2 AQP3 AQP4 AQP7 CLCNKA
2 cellular response to hypoxia GO:0071456 9.69 AQP1 AQP3 CASR
3 chloride transmembrane transport GO:1902476 9.67 CASR CLCNKA SLC12A1
4 excretion GO:0007588 9.65 AQP2 AQP3 AQP7 AVPR2 CLCNKA
5 positive regulation of vasoconstriction GO:0045907 9.63 AVP AVPR2 CASR
6 odontogenesis GO:0042476 9.55 AQP1 AQP3
7 cellular response to copper ion GO:0071280 9.54 AQP1 AQP2
8 multicellular organismal water homeostasis GO:0050891 9.54 AQP1 AQP4 AVP
9 cell volume homeostasis GO:0006884 9.52 AQP1 SLC12A1
10 positive regulation of systemic arterial blood pressure GO:0003084 9.48 AVP AVPR2
11 glycerol transport GO:0015793 9.46 AQP1 AQP2 AQP3 AQP7
12 cellular response to mercury ion GO:0071288 9.43 AQP1 AQP2
13 renal water homeostasis GO:0003091 9.43 AQP1 AQP2 AQP3 AQP4 AVP AVPR2
14 renal water transport GO:0003097 9.4 AQP1 AQP2
15 water transport GO:0006833 9.17 AQP1 AQP2 AQP3 AQP4 AQP7 AVP

Molecular functions related to Diabetes Insipidus, Nephrogenic, Autosomal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 channel activity GO:0015267 9.43 AQP1 AQP2 AQP3 AQP4 AQP7 MIP
2 water transmembrane transporter activity GO:0005372 9.33 AQP1 AQP2 AQP4
3 glycerol channel activity GO:0015254 9.32 AQP3 AQP7
4 glycerol transmembrane transporter activity GO:0015168 9.26 AQP1 AQP2
5 water channel activity GO:0015250 9.1 AQP1 AQP2 AQP3 AQP4 AQP7 MIP

Sources for Diabetes Insipidus, Nephrogenic, Autosomal

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....